Skip to main
DWTX
DWTX logo

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. is a development-stage biotechnology company focused on advancing antiviral therapies for conditions like fibromyalgia and long COVID, with product candidates IMC-1 and IMC-2. The company recently raised its 12-month price target to $12.00 per share, reflecting optimism about the potential future revenues stemming from new assets and a recent licensing agreement for SP16, which expands its therapeutic portfolio. This strategic agreement enables Dogwood to leverage its assets in the cancer-related pain market, reinforcing the company's long-term growth prospects and overall positive outlook.

Bears say

Dogwood Therapeutics Inc, operating in the development stage of biotechnology, has struggled to establish a strong financial footing as it advances its potential antiviral therapies, particularly in the competitive fields addressing complex conditions like fibromyalgia and long COVID. The company’s reliance on product candidates IMC-1 and IMC-2, which are still in the experimental stage, raises concerns regarding viability and the significant capital investment required for clinical development without guaranteed market acceptance or favorable outcomes. Furthermore, the uncertainties surrounding regulatory approvals and the overall market environment for biotech firms could lead to prolonged periods of financial instability, further justifying a cautious outlook on Dogwood Therapeutics’s stock.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.